HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
PAHC
Phibro Animal Health Corporation
PAHC's fundamentals are strong and it looks cheap: trading at 14x earnings, below its usual 21x. Analysts expect strong earnings growth.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
PAHC Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Under pressure | |
| Stable |
PAHC's profitability is currently strong, and its revenue and balance sheet are stable, but its cash flow is under pressure.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
PAHC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 9.8x | $35.46 | — |
| Cheap | 14x | $35.90 | +1.2% |
| Current | 14x | $35.46 | — |
| Fair | 21x | $52.34 | +48% |
| Expensive | 37x | $93.48 | +164% |
Historical ranges are pointers, not guarantees.
PAHC's PE is in its cheap range at 14x. If earnings grow as analysts expect, today's price would be 9.8x next year's earnings.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
PAHC Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
PAHC has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
PAHC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.61 | +44% |
| Q3 2026 | $2.50 | +50% |
| Q2 2026 | $2.43 | +104% |
| Q1 2026 | $2.34 | +200% |
| Q4 2025 | $2.26 | +371% |
| Q3 2025 | $1.67 | +288% |
| Q2 2025 | $1.19 | +1883% |
| Q1 2025 | $0.78 | +144% |
| Q4 2024 | $0.48 | +33% |
PAHC has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over PAHC on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
PAHC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $386.8M | +6.3% |
| Q2 2026 | $396.7M | +4.8% |
| Q1 2026 | $383.5M | +10% |
| Q4 2025 | $373.9M | +21% |
| Q3 2025 | $363.9M | +40% |
| Q2 2025 | $378.7M | +39% |
| Q1 2025 | $347.8M | +32% |
| Q4 2024 | $309.3M | +24% |
PAHC's revenue has grown year over year for 12 quarters in a row: $387M last quarter, up 6.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 13% | -1.3 points |
| Q2 2026 | 12% | +3.2 points |
| Q1 2026 | 12% | +2 points |
| Q4 2025 | 13% | +5.2 points |
| Q3 2025 | 14% | +7.3 points |
| Q2 2025 | 8.9% | +2.2 points |
| Q1 2025 | 9.6% | +2.1 points |
| Q4 2024 | 8.3% | +2 points |
PAHC has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over PAHC on cash flow, with more consistent year-over-year improvement.
PAHC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $7.3M | +$11.8M |
| Q2 2026 | $5.2M | -36% |
| Q1 2026 | $890K | -97% |
| Q4 2025 | $8.3M | +$13M |
| Q3 2025 | -$4.5M | -248% |
| Q2 2025 | $8.1M | -47% |
| Q1 2025 | $35.4M | +2011% |
| Q4 2024 | -$4.7M | -123% |
PAHC still generates free cash flow, though less than at its 2025 peak: $22M over the past year.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over PAHC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
PAHC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -7K shares |
| 1 year | +0.2% | +80K shares |
| 3 years | +1.1% | +453K shares |
| 5 years | +1.1% | +453K shares |
| Available history | +1.1% | +453K shares |
PAHC has 41M diluted shares, about the same as a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
PAHC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.2x | Moderate |
| Q2 2026 | 0.2x | Very low |
| Q1 2026 | 2.5x | Moderate |
| Q4 2025 | 2.6x | Moderate |
| Q3 2025 | 2.9x | Moderate |
| Q2 2025 | 0.1x | Very low |
| Q1 2025 | 4.2x | High |
| Q4 2024 | 4.8x | High |
PAHC's net debt is about 2.2 years of its operating earnings (EBITDA), down from 2.9 years a year ago.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
PAHC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 46.1 | Neutral |
| Stochastic | 36.1 | Neutral |
PAHC's weekly RSI is 46 (neutral) and its Stochastic is 36 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
PAHC PE vs Healthcare Sector
| Metric | PAHC | Sector median | Relative |
|---|---|---|---|
| PE | 14x | 26x | 45% below |
| PE % | 15 | 29 | 14 pts below |
PAHC is trading at 14x earnings, a 45% discount to the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
PAHC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $36.9 | 3.8% below |
| 20 week MA | $35.8 | 0.8% below |
| 50 week MA | $40.6 | 13% below |
| 100 week MA | $34.4 | 3% above |
| 200 week MA | $25.0 | 42% above |
PAHC has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
PAHC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $24.8 | $19.1 | -23% |
| 2021 | $19.1 | $20.7 | +8.3% |
| 2022 | $20.7 | $13.9 | -33% |
| 2023 | $13.9 | $11.6 | -17% |
| 2024 | $11.6 | $21.1 | +82% |
| 2025 | $21.1 | $38.2 | +81% |
| 2026 YTD | $38.2 | $35.5 | -7.1% |
PAHC has the edge over HIMS on returns for 2026, with the stronger performance.